Wedbush Securities

Valkyrie Investments is a specialized alternative asset management firm.

Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach. DNTH103 is a new medicine in development for serious autoimmune diseases. It targets a specific part of the immune system and could be a self-administered injection for some patients.

Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA.

Biotheryx is a clinical stage biopharmaceutical company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) for the treatment of a wide range of diseases with an initial focus on cancer. Members of our founding and scientific teams previously developed the first FDA approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and have applied their expertise in Cereblon binding to build our proprietary PRODEGY platform. Our platform leverages an extensive patent protected and rationally designed library of Cereblon binders that we believe provides us with a differentiated starting point for drug design of molecular glues, bifunctional degraders and hybrid degraders.

ETFMG is a provider of exchange-traded funds (ETFs), with a vision of developing innovative thematic ETFs that provide investors unique exposure to new markets. Today, the ETFMG fund line up provides access to a diverse collection of global themes and is comprised of 75% first to market products. We turn portfolio management strategies into successful ETFs by partnering with market segment experts to bring long-term growth opportunities to investors. ETFMG funds are proof as to the power of the ETF wrapper and that thematic products can have a place in investors’ portfolios.

Alan Kluis has been a commodity advisor and broker since 1976. He is president and managing partner of Kluis Commodities and Kluis Publishing in Wayzata, Minnesota. Alan is an introducing broker with R.J.O'Brien. Alan is also a writer. He writes a column, Your Profit, which appears in every issue of Successful Farming magazine. Alan has published two books on commodities trading. Alan is commonly quoted in major publications including the Wall Street Journal, and is a featured speaker at commodity conferences nationwide. He is a frequent market analyst for the Linder Farm Radio News Network. Alan is the author of the weekly commodity advisory newsletter, The Al Kluis Report and works with a team to send out a daily email report to 3,000 subscribers. Alan, a Minnesota farmboy, was awarded his degree in Ag Economics from the University of Minnesota in 1974, after which he was executive director of the Minnesota Soybean Association before entering the markets full-time. Alan's family still farms in southwest Minnesota and Al enjoys helping with fieldwork when the markets allow.

Oncolytics Biotech focuses the research and development efforts on the development of REOLYSIN, the cancer therapeutic. The product for human use, REOLYSIN is developed from the reovirus. The virus has been demonstrated to replicate in the tumour cells bearing an activated Ras pathway. The Ras protein is a regulator of cell growth and differentiation. It transmits signals from the cell's surface, through growth factor receptors, to downstream elements, which are in turn relayed to the nucleus. The transmission of signals from the cell surface to the cell's nucleus is referred to as the signal transduction. The wholly owned subsidiaries of the company include Oncolytics Biotech (Barbados) Inc. and Oncoltics Biotech (US) Inc. In April 2009, the Company completed the acquisition of an inactive private company. Oncolytics Biotech was founded on 1988 and is based in Calgary, Alberta, Canada.

Pacific Growth Equities is a research driven investment bank that specializes in technology based emerging growth companies. They are dedicated to providing high quality research for institutional investors and superior execution for their corporate clients. The idea of working harder to help institutions understand and invest in complicated growth stocks is not new. Fast moving growth companies and investors in those companies have long relied on a better quality of service from focused investment banks like Pacific Growth Equities. Consolidation in the financial services industry combined with a single minded focus on investment banking revenue among those firms that remain have left investors and companies with an ever dwindling pool of independent, reliable advisors. They offer a full range of investment banking and brokerage services including Public Equity offerings, Private Equity offerings, and Mergers & Acquisitions. Their focus is on those life sciences, technology, healthcare and consumer growth companies where their brand of high value in-depth research makes a difference. Their Sales & Trading team is broad and deep, with on average 15 years of experience working with growth stocks. They enjoy mutually respectful relationships with the top institutional buyers of emerging growth stocks both in the US and abroad. Perhaps most important of all, their clients have immediate access to senior professionals in every area of the firm. They're not only large enough to serve all your investment banking needs, they haven't forgotten that "hands on" management from their top people is critical to successful completion of your transaction. And since they're independent and employee-owned, you're always dealing with someone who owns a piece of the business. Pacific Growth Equities is an entrepreneurial company focused on getting the job done. They have brought together years of experience at old-line investment banks, and eliminated the politics and slow-moving, top-heavy corporate mentality. Their corporate culture was forged in the entrepreneurial climate of the information age, and they often find that their business style is more closely attuned to their entrepreneurial clients than their co-managers. Innovation is part of doing business at Pacific Growth Equities. They have a history of being very creative and coming up with "outside the box" solutions to meet the needs of both their institutional and investment banking clients. They believe that the best ideas have frequently not been tried before.

Valkyrie Investments is a specialized alternative asset management firm at the intersection of traditional finance and the emerging cryptocurrency sector. The firm aims to create and manage portfolios and products, including managing exposure to digital assets and other frontier investments. Valkyrie Investments is led by financial industry veterans with decades of experience across firms including Guggenheim Partners, UBS, Chicago Board of Trade, Chicago Mercantile Exchange, and The World Bank.